QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Full Text Full Text (PDF) Purchase Article View Shopping Cart Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Burnham, E. L. Articles by Ziegler, T. R. Search for Related Content PubMed PubMed Citation Articles by Burnham, E. L. Articles by Ziegler, T. R.

---

Supplement: Nutritional Consequences of Critical Illness Myopathies

Myopathies in Critical Illness: Characterization and Nutritional Aspects^1,2

Department of Medicine, Division of Pulmonary, Allergy, and Critical Care Medicine, and the Division of Endocrinology and Metabolism, Emory University School of Medicine, Atlanta, GA 30322

³To whom correspondence should be addressed. E-mail: eburnha{at}emory.edu.

Myopathies related to critical illness have received increasing recognition over the past decade and are common in patients even after a brief period in the intensive care unit. Recent studies have revealed that myopathies in the critically ill may in fact be more prevalent than neuropathies and that morbidity and mortality may be greater. Protein catabolism, an increase in urinary nitrogen loss, and muscle wasting are observed in critical illness myopathy. Muscle biopsies in critically ill patients demonstrate low glutamine levels, low protein/DNA levels, and high concentrations of extracellular water. The increased flux of glutamine in muscle in these patients is thought to be insufficient to meet the body’s requirement for glutamine, and thus in critical illness this amino acid may be classified as "conditionally essential." Three subtypes of critical illness myopathy have been described that are often grouped together as acute quadriplegic myopathy: thick-filament myopathy, critical illness myopathy, and necrotizing myopathy. These can be differentiated based on clinical features and muscle biopsy. Treatments for critical illness myopathies range from primary prevention, i.e., avoiding myopathy-inducing drugs, to novel nutritional therapies, such as glutamine and glutathione supplementation. One should be particularly vigilant for the development of myopathies in critically ill alcoholic patients, who may have a chronic alcoholic myopathy at baseline. In the past decade, advances have been made in characterizing and identifying patients with myopathies due to critical illness. However, additional studies must be performed in order to develop appropriate therapies for this potentially devastating disorder.

KEY WORDS: • neuromuscular diseases • glutamine • arginine • alcohol abuse • glutathione

This article has been cited by other articles:

				T. R. Ziegler Parenteral Nutrition in the Critically Ill Patient N. Engl. J. Med., September 10, 2009; 361(11): 1088 - 1097. [Full Text] [PDF]

				S Pati, J A Goodfellow, S Iyadurai, and D Hilton-Jones Approach to critical illness polyneuropathy and myopathy Postgrad. Med. J., July 1, 2008; 84(993): 354 - 360. [Abstract] [Full Text] [PDF]

				M. U. Fareed, A. R. Evenson, W. Wei, M. Menconi, V. Poylin, V. Petkova, B. Pignol, and P.-O. Hasselgren Treatment of rats with calpain inhibitors prevents sepsis-induced muscle proteolysis independent of atrogin-1/MAFbx and MuRF1 expression Am J Physiol Regulatory Integrative Comp Physiol, June 1, 2006; 290(6): R1589 - R1597. [Abstract] [Full Text] [PDF]

				B. W. Tobin and P. N. Uchakin Nutritional Consequences of Critical Illness Myopathies J. Nutr., July 1, 2005; 135(7): 1803S - 1805S. [Full Text] [PDF]